SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-150555
Filing Date
2023-05-22
Accepted
2023-05-22 16:45:54
Documents
14
Period of Report
2023-05-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d434201d8k.htm   iXBRL 8-K 29136
2 EX-99.1 d434201dex991.htm EX-99.1 13078
6 GRAPHIC g434201g0522043523471.jpg GRAPHIC 3135
  Complete submission text file 0001193125-23-150555.txt   175655

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20230522.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20230522_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20230522_pre.xml EX-101.PRE 11264
8 EXTRACTED XBRL INSTANCE DOCUMENT d434201d8k_htm.xml XML 3360
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 23945195
SIC: 2836 Biological Products, (No Diagnostic Substances)